 LEXINGTON, Mass., Feb. 11, 2021 GLOBE NEWSWIRE -- Kaleido Biosciences, Inc. Nasdaq: KLDO, a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that, in connection with its previously announced underwritten public offering of common stock, the underwriters have fully exercised their option to purchase an additional 787,500 shares of common stock from the Company. The exercise of this option increases the size of the offering to an aggregate of 6,037,500 shares at a price to the public of 11.50 per share. The gross proceeds to Kaleido from this offering were approximately 69.4 million, before deducting underwriting discounts and commissions and other offering expenses. The purchase of the additional shares of common stock closed on February 11, 2021. 